vs
Side-by-side financial comparison of Phathom Pharmaceuticals, Inc. (PHAT) and TRICO BANCSHARES (TCBK). Click either name above to swap in a different company.
TRICO BANCSHARES is the larger business by last-quarter revenue ($109.4M vs $57.6M, roughly 1.9× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs 9.0%). TRICO BANCSHARES produced more free cash flow last quarter ($127.9M vs $-167.0M).
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
Trico Bancshares is a U.S.-headquartered regional bank holding company operating Tri Counties Bank. It offers a full range of retail and commercial banking services including deposit products, mortgages, small business loans, and wealth management, primarily serving consumers and SMEs in Northern California.
PHAT vs TCBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.6M | $109.4M |
| Net Profit | — | $33.6M |
| Gross Margin | 86.7% | — |
| Operating Margin | — | 42.6% |
| Net Margin | — | 251.6% |
| Revenue YoY | 94.1% | 9.0% |
| Net Profit YoY | 71.6% | 15.8% |
| EPS (diluted) | — | $1.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.6M | $109.4M | ||
| Q3 25 | $49.5M | $107.6M | ||
| Q2 25 | $39.5M | $103.6M | ||
| Q1 25 | $28.5M | $98.6M | ||
| Q4 24 | $29.7M | $100.4M | ||
| Q3 24 | $16.4M | $99.1M | ||
| Q2 24 | $7.3M | $97.9M | ||
| Q1 24 | — | $98.5M |
| Q4 25 | — | $33.6M | ||
| Q3 25 | $-30.0M | $34.0M | ||
| Q2 25 | $-75.8M | $27.5M | ||
| Q1 25 | $-94.3M | $26.4M | ||
| Q4 24 | — | $29.0M | ||
| Q3 24 | $-85.6M | $29.1M | ||
| Q2 24 | $-91.4M | $29.0M | ||
| Q1 24 | — | $27.7M |
| Q4 25 | 86.7% | — | ||
| Q3 25 | 87.5% | — | ||
| Q2 25 | 87.2% | — | ||
| Q1 25 | 86.9% | — | ||
| Q4 24 | 87.1% | — | ||
| Q3 24 | 85.6% | — | ||
| Q2 24 | 81.2% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 42.6% | ||
| Q3 25 | -30.8% | 43.2% | ||
| Q2 25 | -151.7% | 36.5% | ||
| Q1 25 | -276.5% | 35.8% | ||
| Q4 24 | — | 38.7% | ||
| Q3 24 | -433.0% | 39.8% | ||
| Q2 24 | -1055.4% | 40.0% | ||
| Q1 24 | — | 38.3% |
| Q4 25 | — | 251.6% | ||
| Q3 25 | -60.5% | 31.6% | ||
| Q2 25 | -191.9% | 26.6% | ||
| Q1 25 | -330.7% | 26.7% | ||
| Q4 24 | — | 221.4% | ||
| Q3 24 | -523.3% | 29.3% | ||
| Q2 24 | -1248.6% | 29.7% | ||
| Q1 24 | — | 28.2% |
| Q4 25 | — | $1.02 | ||
| Q3 25 | $-0.41 | $1.04 | ||
| Q2 25 | $-1.05 | $0.84 | ||
| Q1 25 | $-1.31 | $0.80 | ||
| Q4 24 | — | $0.88 | ||
| Q3 24 | $-1.32 | $0.88 | ||
| Q2 24 | $-1.56 | $0.87 | ||
| Q1 24 | — | $0.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $130.0M | $157.0M |
| Total DebtLower is stronger | $209.1M | — |
| Stockholders' EquityBook value | $-438.2M | $1.3B |
| Total Assets | $259.1M | $9.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $130.0M | $157.0M | ||
| Q3 25 | $135.2M | $298.8M | ||
| Q2 25 | $149.6M | $314.3M | ||
| Q1 25 | $212.3M | $308.3M | ||
| Q4 24 | $297.3M | $145.0M | ||
| Q3 24 | $334.7M | $320.1M | ||
| Q2 24 | $276.2M | $206.6M | ||
| Q1 24 | — | $82.8M |
| Q4 25 | $209.1M | — | ||
| Q3 25 | $207.1M | — | ||
| Q2 25 | $205.1M | — | ||
| Q1 25 | $203.2M | — | ||
| Q4 24 | $201.4M | — | ||
| Q3 24 | $175.7M | — | ||
| Q2 24 | $174.4M | — | ||
| Q1 24 | — | — |
| Q4 25 | $-438.2M | $1.3B | ||
| Q3 25 | $-422.5M | $1.3B | ||
| Q2 25 | $-405.8M | $1.3B | ||
| Q1 25 | $-338.4M | $1.3B | ||
| Q4 24 | $-253.6M | $1.2B | ||
| Q3 24 | $-187.1M | $1.2B | ||
| Q2 24 | $-233.8M | $1.2B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | $259.1M | $9.8B | ||
| Q3 25 | $240.3M | $9.9B | ||
| Q2 25 | $250.2M | $9.9B | ||
| Q1 25 | $294.2M | $9.8B | ||
| Q4 24 | $378.3M | $9.7B | ||
| Q3 24 | $387.0M | $9.8B | ||
| Q2 24 | $319.4M | $9.7B | ||
| Q1 24 | — | $9.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-166.8M | $133.3M |
| Free Cash FlowOCF − Capex | $-167.0M | $127.9M |
| FCF MarginFCF / Revenue | -290.0% | 116.9% |
| Capex IntensityCapex / Revenue | 0.4% | 4.9% |
| Cash ConversionOCF / Net Profit | — | 3.96× |
| TTM Free Cash FlowTrailing 4 quarters | $-328.9M | $222.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-166.8M | $133.3M | ||
| Q3 25 | $-14.1M | $45.1M | ||
| Q2 25 | $-62.7M | $29.2M | ||
| Q1 25 | $-84.9M | $24.5M | ||
| Q4 24 | $-266.8M | $109.7M | ||
| Q3 24 | $-63.6M | $28.6M | ||
| Q2 24 | $-70.7M | $31.8M | ||
| Q1 24 | — | $25.1M |
| Q4 25 | $-167.0M | $127.9M | ||
| Q3 25 | $-14.1M | $43.2M | ||
| Q2 25 | $-62.8M | $28.2M | ||
| Q1 25 | $-84.9M | $22.8M | ||
| Q4 24 | $-266.9M | $105.2M | ||
| Q3 24 | $-63.6M | $27.3M | ||
| Q2 24 | $-70.8M | $30.8M | ||
| Q1 24 | — | $24.1M |
| Q4 25 | -290.0% | 116.9% | ||
| Q3 25 | -28.6% | 40.2% | ||
| Q2 25 | -159.0% | 27.2% | ||
| Q1 25 | -297.9% | 23.1% | ||
| Q4 24 | -899.8% | 104.8% | ||
| Q3 24 | -389.0% | 27.6% | ||
| Q2 24 | -966.2% | 31.5% | ||
| Q1 24 | — | 24.4% |
| Q4 25 | 0.4% | 4.9% | ||
| Q3 25 | 0.1% | 1.7% | ||
| Q2 25 | 0.2% | 1.0% | ||
| Q1 25 | 0.1% | 1.7% | ||
| Q4 24 | 0.5% | 4.5% | ||
| Q3 24 | 0.3% | 1.3% | ||
| Q2 24 | 0.6% | 1.0% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | 3.96× | ||
| Q3 25 | — | 1.33× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 3.78× | ||
| Q3 24 | — | 0.98× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | — | 0.90× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
